首页> 美国卫生研究院文献>Nephrology Dialysis Transplantation >Multicenter open-label extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

【2h】

Multicenter open-label extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

机译：一项多中心开放标签扩展试验评估托伐普坦在常染色体显性多囊肾疾病中早期治疗与延迟治疗的长期疗效和安全性：TEMPO 4：4试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundIn TEMPO 3:4, the vasopressin V2 receptor antagonist tolvaptan slowed total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline relative to placebo.

机译：背景技术在TEMPO 3：4中，相对于安慰剂，血管加压素V2受体拮抗剂托伐普坦减慢了总肾脏体积（TKV）的增长，并降低了估计的肾小球滤过率（eGFR）。

著录项

期刊名称 Nephrology Dialysis Transplantation
作者
Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Ann Dandurand; John Ouyang; Frank S Czerwiec; Jaime D Blais;
展开▼
作者单位

展开▼
年(卷),期 -1(33),3
年度 -1
页码 477–489
总页数 13
原文格式 PDF
正文语种
中图分类泌尿科学（泌尿生殖系疾病）;小儿泌尿科学;肾疾病;移植;
关键词
autosomal dominant polycystic kidney disease chronic kidney disease polycystin kidney disease vasopressin vasopressin v2 receptor antagonist;

机译：常染色体显性遗传性多囊肾;慢性肾脏病;多囊肾;血管加压素;血管加压素v2受体拮抗剂;

相似文献

外文文献
中文文献
专利

1. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial [J] . Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association . 2017,第7期

机译：多中心，开放标签，扩展试验，以评估早期的长期疗效和安全性与托洛瓦顿血栓溶膜中托尔韦氏植物的延迟治疗促进肾脏疾病：Tempo 4：4试验
2. Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum] [J] . Muto S, Okada T, Yasuda M Drug, Healthcare and Patient Safety . 2018,第3期

机译：托伐普坦在常染色体显性遗传性多囊肾病患者中的长期安全性：TEMPO延长日本试验[更正]
3. Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [J] . Satoru Muto, Tadashi Okada, Moriyoshi Yasuda, Drug, Healthcare and Patient Safety . 2017,第1期

机译：托伐普坦在常染色体显性遗传性多囊肾疾病患者中的长期安全性：TEMPO Extension Japan试验
4. Detection and Segmentation of Kidneys from Magnetic Resonance Images in Patients with Autosomal Dominant Polycystic Kidney Disease [C] . Antonio Brunetti, Giacomo Donato Cascarano, Irio De Feudis, International conference on intelligent computing . 2019

机译：常染色体显性多囊性肾脏病患者的磁共振图像肾脏检测与分割
5. Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial [D] . Saeki Masaomi, 佐伯将臣 2019

机译：充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性：一项多中心，对照，开放标签的临床试验
6. Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial Corrigendum [O] . 2018

机译：托伐普坦在常染色体显性遗传性多囊肾病患者中的长期安全性：TEMPO延长日本试验更正
7. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial [O] . Vicente E Torres, Arlene B Chapman, Olivier Devuyst, 2017

机译：多中心，开放标签，扩展试验，以评估早期的长期疗效和安全性与托洛瓦顿血栓溶膜中托尔韦氏植物的延迟治疗促进肾脏疾病：Tempo 4：4试验

Multicenter open-label extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

摘要

著录项

相似文献

相关主题

期刊订阅